Alpha Teknova (NASDAQ:TKNO) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Alpha Teknova (NASDAQ:TKNO) released its quarterly earnings data on Wednesday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01, FiscalAI reports. Alpha Teknova had a negative return on equity of 24.41% and a negative net margin of 34.76%. The business had revenue of $12.70 million for the quarter, compared to analysts’ expectations of $11.71 million.

Here are the key takeaways from Alpha Teknova’s conference call:

• Teknova posted a second consecutive quarterly revenue record, up 22% year over year. Growth was led by custom products for life science tools and diagnostics customers, with an encouraging but still early uptick in biopharma demand; Clinical Solutions revenue rose 86% from a small, lumpy base.
• New offerings are showing early traction: Build-Tek has generated quote requests from more than 100 organizations, while over 60% of Fill-Tek orders quoted so far are for GMP-grade products. Management sees these tools as ways to attract custom demand and deepen customer relationships, though Fill-Tek’s larger revenue contribution may take years to develop.
• Gross margin increased to 38.0% from 30.7%, and the net loss narrowed to $3.5 million from $4.3 million year over year. Adjusted EBITDA loss and free cash outflow also improved, although the company remains unprofitable.
• Teknova raised its 2026 revenue guidance to $46 million–$48 million and expects full-year free cash outflow below $8 million. Management said a positive Adjusted EBITDA quarter could come before the end of 2027 if markets strengthen and commercial investments deliver, while forecasting at least $8 million of operating expenses in Q4.
• The recovery remains uneven: small and mid-sized biotech discovery spending, including catalog demand, is still soft, and management said it wants to see the funding-driven improvement continue for another few quarters. The company also completed a $46 million equity raise, which strengthens its balance sheet but expands its share count.

Alpha Teknova Stock Up 2.8%

Shares of TKNO stock traded up $0.22 on Friday, hitting $8.10. 65,127 shares of the stock were exchanged, compared to its average volume of 262,081. The company has a current ratio of 4.49, a quick ratio of 3.48 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $434.99 million, a P/E ratio of -27.86 and a beta of 0.96. The business has a 50-day moving average of $7.72 and a 200 day moving average of $4.96. Alpha Teknova has a fifty-two week low of $1.91 and a fifty-two week high of $9.48.

Analyst Ratings Changes

TKNO has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Alpha Teknova from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. TD Cowen lifted their price target on shares of Alpha Teknova from $7.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Jefferies Financial Group initiated coverage on shares of Alpha Teknova in a report on Thursday, September 17th. They issued a “buy” rating and a $9.00 price target for the company. Roth Capital started coverage on shares of Alpha Teknova in a research report on Wednesday, August 5th. They set a “buy” rating and a $7.00 price objective for the company. Finally, BTIG Research raised shares of Alpha Teknova from a “neutral” rating to a “buy” rating and set a $8.00 price objective for the company in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

About Alpha Teknova

Alpha Teknova, Inc is a life sciences company that develops and manufactures critical reagents and other products used in biomedical research, biopharmaceutical development and advanced therapies. The company provides laboratory and production materials designed to support applications including cell and gene therapy, molecular diagnostics, next-generation sequencing, vaccine development and pharmaceutical manufacturing.

Its offerings include research-use-only and current Good Manufacturing Practice (cGMP) reagents, buffers, media and other custom-formulated solutions.